Bulgaria's Sopharma Cuts 9-Mo Cons Net Profit despite Rise in Sales

Bulgaria's Sopharma Cuts 9-Mo Cons Net Profit despite Rise in Sales

Bulgarian drug maker Sopharma said on Thursday that its consolidated net profit, excluding interest attributable to minority shareholders in the group's subsidiaries, fell to 30.0 million levs ($17.4 million/15.3 million euro) in the first nine months of the year from 32.7 million levs in the same period of 2017.The company's sales revenue rose 19.6% year-on-year to 860.9 million levs in January-September, mainly due to the consolidation of Serbian drug trader Lekovit, Sopharma said in an interim financial statement. Sopharma's majority-owned unit Sopharma Trading acquired a 70% stake in Lekovit in August 2017.Sopharma booked 65% of its total sales in Bulgaria, while 33% came from exports to Europe. The drug maker booked total operating revenue of 872.0 million levs in the review period, up from 733.5 million levs in the comparable period of 2017.

Previous Next
Test Caption
Test Description goes like this
Cookies Preferences
Choose Type of Cookies You Accept Using

These cookies are required for the website to run and cannot be switched off. Such cookie are only set in response to actions made by you such as language, currency, login session, privacy preferences. You can set your browser to block these cookies but our site may not work then.

These cookies allow us to measure visitors traffic and see traffic sources by collecting information in data sets. They also help us understand which products and actions are more popular than others.

These cookies are usually set by our marketing and advertising partners. They may be used by them to build a profile of your interest and later show you relevant ads. If you do not allow these cookies you will not experience targeted ads for your interests.